Olin Biotech announced that it has recently been concerned about false statements about the company's recombinant Staphylococcus aureus vaccine phase III clinical trial data on some online platforms. Phase III clinical trial results, including 73.25% protective efficacy data disclosed by the company, were calculated by an independent third party statistics team, and the company faithfully disclosed the information based on the report issued by the independent third party. After verification, the data used in the “Recombinant Staphylococcus aureus Vaccine Phase III Clinical Data Audit Report” published online, such as the number of confirmed cases and the total number of subjects, and their findings were all inconsistent with the actual situation of the company's clinical trials.

Olin Biotech announced that it has recently been concerned about false statements about the company's recombinant Staphylococcus aureus vaccine phase III clinical trial data on some online platforms. Phase III clinical trial results, including 73.25% protective efficacy data disclosed by the company, were calculated by an independent third party statistics team, and the company faithfully disclosed the information based on the report issued by the independent third party. After verification, the data used in the “Recombinant Staphylococcus aureus Vaccine Phase III Clinical Data Audit Report” published online, such as the number of confirmed cases and the total number of subjects, and their findings were all inconsistent with the actual situation of the company's clinical trials.